Bacteremia due to ESKAPE pathogens: An emerging problem in cancer patients

J Egypt Natl Canc Inst. 2016 Sep;28(3):157-62. doi: 10.1016/j.jnci.2016.05.002. Epub 2016 Jun 3.

Abstract

Background and aim: In recent years, a few of the antibiotic-resistant bacteria, known as ESKAPE pathogens, have been found responsible for serious infections. We investigated the risk factors, and impact of ESKAPE pathogens on course of blood stream infections (BSIs) in cancer patients in comparison to coagulase negative Staphylococci (CoNS).

Patients and methods: The data of patients with ESKAPE positive blood cultures at National Cancer Institute, Cairo University were analyzed. Identification and antimicrobial susceptibility of isolates were done using Microscan Walk Away 96.

Results: In a 6month period, ESKAPE pathogens were isolated from non-duplicate blood cultures in 81 episodes of 72 cases of pediatric cancer patients, while CoNS were isolated from 135 blood cultures of 116 patients. The ESKAPE pathogens isolated were Enterobacter spp., methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterococci in 12%, 23%, 37%, 10%, 9%, and 9% of episodes, respectively. Health-care acquired infections constituted 75% of ESKAPE infections. Duration of episodes and overall mortality were significantly higher in ESKAPE BSIs when compared to CoNS (14.5±7.6 versus 09.9±6.9), and (26% versus 4%); respectively, p value <0.001.

Conclusions: ESKAPE pathogens were significantly associated with higher rates of morbidity and mortality indicating the need for improving the means of prevention of these types of infections within health care premises. Microbiology laboratories have a role in defining more dangerous infections and rapid diagnostics are required in the era of resistance.

Keywords: Blood stream infection; Cancer patients; ESKAPE.

MeSH terms

  • Acinetobacter baumannii / isolation & purification
  • Acinetobacter baumannii / pathogenicity
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / complications
  • Bacteremia / microbiology*
  • Bacteremia / pathology
  • Cross Infection / complications
  • Cross Infection / microbiology*
  • Cross Infection / pathology
  • Drug Resistance, Bacterial / genetics*
  • Enterobacter / isolation & purification
  • Enterobacter / pathogenicity
  • Female
  • Humans
  • Klebsiella pneumoniae / isolation & purification
  • Klebsiella pneumoniae / pathogenicity
  • Male
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification
  • Methicillin-Resistant Staphylococcus aureus / pathogenicity
  • Neoplasms / complications
  • Neoplasms / microbiology*
  • Neoplasms / pathology
  • Pseudomonas aeruginosa / isolation & purification
  • Pseudomonas aeruginosa / pathogenicity
  • Risk Factors

Substances

  • Anti-Bacterial Agents